By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) 

25 Science Park
Room 561
New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-5606 Fax: 203-624-5627


SEARCH JOBS



Segment
Drug Discovery





Company News
Malin Corporation (MLC.IR) Investee Company - Melinta - To Be Transformed Into A NASDAQ Listed Company 8/10/2017 6:40:07 AM
Ligand (LGND)’s Partner Melinta Announces U.S. FDA Approval Of Baxdela (Delafloxacin) For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 6/20/2017 11:12:08 AM
Melinta Announces FDA Approval Of Baxdela (Delafloxacin) For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 6/20/2017 10:40:38 AM
Melinta Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid 3/2/2017 9:44:09 AM
Melinta And Menarini Group Enter Into Commercial And Co-Development Agreement For Delafloxacin In 68 Countries 3/2/2017 9:41:40 AM
Melinta New Drug Application For Baxdela Accepted For Filing By FDA 1/5/2017 7:35:14 AM
Ligand (LGND) Partner Melinta Submits Baxdela New Drug Application For Hospital-Treated Skin Infections 10/24/2016 8:43:25 AM
Melinta's Baxdela Successfully Achieves Primary Endpoints in Late Stage Study 5/12/2016 7:07:31 AM
Melinta Appoints Dr. Eugene Sun As Chief Executive Officer 4/19/2016 8:02:22 AM
Melinta Appoints John Temperato President And Chief Operating Officer 2/23/2016 8:04:57 AM
12345678910
//-->